Opendata, web and dolomites

3DProSeed

3DProSeed: the first ready-to-use, pre-assembled, hydrogel microtiter plate for 3D cell culturess

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 3DProSeed project word cloud

Explore the words cloud of the 3DProSeed project. It provides you a very rough idea of what is the project "3DProSeed" about.

operative    tool    surface    successful    2d    handling    missed    giving    launch    matrix    consistency    billion    integration    12    tissues    mimic    investment    2018    efficacy    ing    3d    drugs    screenings    fast    solutions    stages    difficult    human    capital    compound    screening    22    period    predictable    10    aberrantly    molecule    microtiter    encapsulating    vivo    21    mostly    stimuli    data    first    simplicity    discoveries    revenues    culture    flat    advantages    discovery    organs    progress    reduce    assembled    hydrogel    15    clinical    assays    successfully    cell    differ    failures    3dproseed    cultures    drug    stage    inside    last    contrast    ones    vitro    company    manufacturing    reproducibility    significantly    cagr2013    power    compounds    ready    provides    impacting    workflow       trial       predictive    realistically    poor    behaviours    pharmaceuticals    patented    handle    physiological    96    environment    animal    plates    found    quantified    market    consumable    intensive    rate    bench   

Project "3DProSeed" data sheet

The following table provides information about the project.

Coordinator
ECTICA TECHNOLOGIES AG 

Organization address
address: TRAMSTRASSE 77
city: ZURICH
postcode: 8050
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.ectica-technologies.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECTICA TECHNOLOGIES AG CH (ZURICH) coordinator 50˙000.00

Map

 Project objective

Capital investment in new pharmaceuticals to get from bench to clinical trial is estimated to be $1 billion per successful molecule, and only 10% of the compounds progress successfully through clinical development. Cell-based assays screenings are the key tool used to assess the potential efficacy of a new compound in drug discovery, as it provides a simple, fast, and cost-effective approach to avoid large-scale and cost-intensive animal testing at early stages. Therefore, the development of in vitro cell-based systems that can more realistically mimic the in vivo cell behaviours is a raising market, with a CAGR2013-2018 of 12.4% growth rate and quantified in $21.6 billion by 2018. Drug research cell-based assays are mostly conducted with cell cultures on flat surface (2D), but they differ from human tissues significantly and can respond aberrantly to stimuli, resulting in missed discoveries and late-stage clinical failures of drugs in development. In contrast, 3D cell systems have a greater predictable power as they can better mimic the physiological environment in organs and tissues. Still, 2D cell culture systems offer advantages like the simplicity of handling and high data reproducibility that are not found in the current 3D cell systems. The last ones are very difficult to handle and not ready-to-use ones, giving poor consistency, data reproducibility and poor workflow integration. In response, we have developed 3DProSeed, the first ready-to-use solutions in the 3D cell culture market. Based on a patented novel process for manufacturing and encapsulating the cell growth matrix, known as hydrogel, inside 96-microtiter plates, we will be able to launch to the market the first ready-to-use, pre-assembled, hydrogel-based consumable products for pre-clinical screening development. As a result, 3DProSeed will reduce the operative cost up of R&D to 15%, will increase predictive efficacy of assays, impacting on our company with €15.22 M revenues after 5-years period.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3DPROSEED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "3DPROSEED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

SUPPLEPRINT (2018)

Super Productive Line Printing Inkjet

Read More  

Volumizer (2018)

A natural, non-surgical, and safe facial filler which treats the root cause of facial ageing.

Read More  

STAR (2018)

Safe, Transparent, Active and Reliable mineral sunscreen technology

Read More